30 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Heteroatom analogues of bemoradan: chemistry and cardiotonic activity of 1,4-benzothiazinylpyridazinones.
R. W. Johnson Pharmaceutical Research Institute
2-Substituted 1-azabicycloalkanes, a new class of non-opiate antinociceptive agents.
R. W. Johnson Pharmaceutical Research Institute
6-Benzoxazinylpyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents.
R. W. Johnson Pharmaceutical Research Institute
SAR studies of diaryltriazoles against bacterial two-component regulatory systems and their antibacterial activities.
R. W. Johnson Pharmaceutical Research Institute
Novel inhibitors of bacterial two-component systems with gram positive antibacterial activity: pharmacophore identification based on the screening hit closantel.
R. W. Johnson Pharmaceutical Research Institute
DNA gyrase inhibitory activity of ellagic acid derivatives.
R. W. Johnson Pharmaceutical Research Institute
Synthesis and structure-activity relationship of novel pyridyl ethers for the nicotinic acetylcholine receptor.
R. W. Johnson Pharmaceutical Research Institute
Orally active benzamide antipsychotic agents with affinity for dopamine D2, serotonin 5-HT1A, and adrenergic alpha1 receptors.
R. W. Johnson Pharmaceutical Research Institute
Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group.
R. W. Johnson Pharmaceutical Research Institute
Nonsteroidal progesterone receptor ligands. 2. High-affinity ligands with selectivity for bone cell progesterone receptors.
R. W. Johnson Pharmaceutical Research Institute
N-aryl-N'-benzylpiperazines as potential antipsychotic agents.
R. W. Johnson Pharmaceutical Research Institute
Piperazinylalkyl heterocycles as potential antipsychotic agents.
R. W. Johnson Pharmaceutical Research Institute
Novel thiazole-based heterocycles as selective inhibitors of fibrinogen-mediated platelet aggregation.
R. W. Johnson Pharmaceutical Research Institute
HMG-CoA reductase inhibitors: design, synthesis, and biological activity of tetrahydroindazole-substituted 3,5-dihydroxy-6-heptenoic acid sodium salts.
R. W. Johnson Pharmaceutical Research Institute
Pyrrole mannich bases as potential antipsychotic agents.
R. W. Johnson Pharmaceutical Research Institute
Benzothiazole hydroxy ureas as inhibitors of 5-lipoxygenase: use of the hydroxyurea moiety as a replacement for hydroxamic acid.
R. W. Johnson Pharmaceutical Research Institute
Piperazinyl benzamidines: synthesis and affinity for the delta opioid receptor.
R. W. Johnson Pharmaceutical Research Institute
Thrombin receptor (PAR-1) antagonists. Heterocycle-based peptidomimetics of the SFLLR agonist motif.
R. W. Johnson Pharmaceutical Research Institute
Synthesis and binding affinities of 4-diarylaminotropanes, a new class of delta opioid agonists.
R. W. Johnson Pharmaceutical Research Institute
The development of novel and selective p56lck tyrosine kinase inhibitors.
R. W. Johnson Pharmaceutical Research Institute
Azepinoindole derivatives with high affinity for brain dopamine and serotonin receptors.
R. W. Johnson Pharmaceutical Research Institute
Nonsteroidal progesterone receptor ligands. 1. 3-Aryl-1-benzoyl-1,4,5,6-tetrahydropyridazines.
R. W. Johnson Pharmaceutical Research Institute
Synthesis and 5-lipoxygenase inhibitory activities of some novel 2-substituted 5-benzofuran hydroxamic acids.
R. W. Johnson Pharmaceutical Research Institute
A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects.
R. W. Johnson Pharmaceutical Research Institute
Design and evaluation of nonpeptide fibrinogen gamma-chain based GPIIb/IIIa antagonists.
R. W. Johnson Pharmaceutical Research Institute
Novel thiazole based heterocycles as inhibitors of LFA-1/ICAM-1 mediated cell adhesion.
R. W. Johnson Pharmaceutical Research Institute
